RecruitingPhase 2NCT07089992

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

URSa-1: A Minibasket Study of Pembrolizumab in Ultra-Rare Sarcomas

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

32 participants

Start Date

Dec 4, 2025

Study Type

INTERVENTIONAL

Conditions

Sarcoma

Summary

The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also study how the immune system responds to the study treatment. Pembrolizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1 (PD-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests the immunotherapy drug pembrolizumab in people with rare types of sarcoma (cancers of connective tissues) that have very few treatment options. The types of sarcoma included are pleomorphic liposarcoma, PEComa, epithelioid sarcoma, CIC-rearranged sarcoma, and sclerosing epithelioid fibrosarcoma / low-grade fibromyxoid sarcoma. **You may be eligible if...** - You have a confirmed diagnosis of one of the five qualifying rare sarcoma types listed above - Your disease has progressed after at least one prior treatment - You have measurable disease on imaging - You have adequate organ function and performance status **You may NOT be eligible if...** - You have a different type of sarcoma not listed in the study - You have active autoimmune disease requiring systemic treatment - You have previously received pembrolizumab or similar immunotherapy drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.